Loading...
If your product does not perform as described on this datasheet, we will refund or replace your product...
Read our guarantee »Products:Cardiovascular >> Blood >> Serum Proteins
Anti-Von Willebrand Factor antibody [4F9]
See all Von Willebrand Factor products (23) ...
Mouse monoclonal [4F9] to Von Willebrand Factor
IF, Flow Cyt, IHC-Frmore details
Reacts with
Human
FVIII: C/vWF complex (denaturated)
Liquid
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Preservative: None
Constituents: PBS, 1mg/ml BSA
Concentration information loading...
Protein A purified
Monoclonal
4F9
IgG1
kappa
Stem Cells >> Endothelial Progenitors >> Endothelial Markers
Cancer >> Invasion/microenvironment >> Angiogenesis >> Angiogenic growth factors
Cardiovascular >> Blood >> Coagulation >> Regulatory
Cardiovascular >> Blood >> Coagulation >> Extrinsic
Cardiovascular >> Blood >> Platelets
Cardiovascular >> Blood >> Serum Proteins
Our Abpromise guarantee covers the use of ab20435 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IF: Use 5µg for 105 cells.
Flow Cyt: Use 2µg for 105 cells. (. ab20435 has been used in flow cytometry with Jurkat cells and with platelets. The Jurkat cell line was fixed using 1% formaldehyde followed by permeabilization using a commercially-available saponin reagent for permeabilization. The platelets were fixed using 1% formaldehyde, washed and suspended in PBS without permeabilization.)
IHC-Fr: 1/50 - 1/100.
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Plasma.
Defects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Contains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
All cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
Target information above from: UniProt accessionP04275
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
ab20435 has not yet been referenced specifically in any publications.
Publishing research using ab20435? Please let us know so that we can cite the reference in this datasheet
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
0
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Call 01223 696 000 or contact us
